Advertisement

Tumor Biology

, Volume 37, Issue 4, pp 4439–4444 | Cite as

Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer

  • Changming Liu
  • Ying Zhang
  • Haijun Chen
  • Lixing Jiang
  • Daping Xiao
Original Article

Abstract

MiR-92a was identified as an essential oncogene by promoting the cell proliferation through FBXW7 in gastric cancer (GC). The function of the single nucleotide polymorphism (SNP) located in the mature region of miR-92a (rs9589207) has not been investigated. We found that rs9589207 in miR-92a was involved in the occurrence of GC by acting as a tumor protective factor and was highly associated with tumor size in GC patients instead of tumor number or metastasis in 554 GC patients and 531 cancer-free controls. Besides, the AA genotype in miR-92a could attenuate the promoting function of miR-92a in cell proliferation with an incapacitation in downregulating the expression of FBXW7. In conclusion, rs9589207 in miR-92a was highly associated with a decreased risk of GC in Chinese Han population and might serve as a novel biomarker for the disease.

Keywords

Genotype MiR-92a Tumor growth FBXW7 SNP 

Notes

Acknowledgments

This work was supported by the Social Development Technology Projects of Kunshan City, China (KS1255 to Changming Liu), Wujin Science and Technique Development Foundation (social development) (WS201414 to Lixin Jiang), Clinical Science and Technique Development Foundation of Jiangsu University (20140039 to Lixing Jiang), and Medical science and technology innovation project of Nanjing Military Region (no. 14ZD24 to Daping Xiao).

Compliance with ethical standards

Conflicts of interest

None

Supplementary material

13277_2015_4288_MOESM1_ESM.pdf (345 kb)
Online Resource 1 (PDF 345 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang K, Liang Q, Li X, Tsoi H, Zhang J, Wang H, et al. MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome. Gut. 2015. doi: 10.1136/gutjnl-2015-309276.Google Scholar
  4. 4.
    Zhang SY, Zhang SQ, Nagaraju GP, El-Rayes BF. Biomarkers for personalized medicine in GI cancers. Mol Aspects Med. 2015. doi: 10.1016/j.mam.2015.06.002.Google Scholar
  5. 5.
    Uthman OA, Jadidi E, Moradi T. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. J Epidemiol Community Health. 2013;67:854–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, et al. MicroRNA214 is associated with progression of ulcerative colitis, and inhibition reduces development of colitis and colitis-associated cancer in mice. Gastroenterology. 2015;149(4):981–992.e11. doi: 10.1053/j.gastro.2015.05.057.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Nie H, Li J, Yang XM, Cao QZ, Feng MX, Xue F, et al. Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology. 2015;62(4):1145–59. doi: 10.1002/hep.27940.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fang F, Chang RM, Yu L, Lei X, Xiao S, Yang H, et al. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J Hepatol. 2015;63(4):874–85. doi: 10.1016/j.jhep.2015.05.008.CrossRefPubMedGoogle Scholar
  9. 9.
    Belgardt BF, Ahmed K, Spranger M, Latreille M, Denzler R, Kondratiuk N, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med. 2015;21:619–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell. 2015;160:1099–110.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hu N, Wang Z, Song X, Wei L, Kim BS, Freedman ND, et al. Genome-wide association study of gastric adenocarcinoma in Asia: a comparison of associations between cardia and non-cardia tumours. Gut. 2015.Google Scholar
  12. 12.
    Espinosa-Parrilla Y, Munoz X, Bonet C, Garcia N, Vencesla A, Yiannakouris N, et al. Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC-EURGAST study. Int J Cancer. 2014;135:2065–76.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang L, Gao J, Zhou D, Bao F. Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to gastric cancer: a meta-analysis. Turk J Gastroenterol. 2015;26(5):378–85. doi: 10.5152/tjg.2015.6603.CrossRefPubMedGoogle Scholar
  14. 14.
    Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, Millikan RC. Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control. 2013;24:1099–109.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhou C, Shen L, Mao L, Wang B, Li Y, Yu H. miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7. Biochem Biophys Res Commun. 2015;458:63–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, et al. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis. 2014;5:e1549.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27:5959–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo WD, et al. Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of mir-363-3p. Gynecol Oncol. 2014;135:565–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci. 2010;101:2241–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Color Dis. 2013;28:19–24.CrossRefGoogle Scholar
  21. 21.
    Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, et al. MicroRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem. 2011;286:10725–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Yumimoto K, Akiyoshi S, Ueo H, Sagara Y, Onoyama I, Ohno S, et al. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Invest. 2015;125:621–35.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, et al. P53-altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009;69:3788–94.CrossRefPubMedGoogle Scholar
  24. 24.
    Xu Y, Swartz KL, Siu KT, Bhattacharyya M, Minella AC. Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism. Oncogene. 2014;33:3161–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8:83–93.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Changming Liu
    • 1
  • Ying Zhang
    • 1
  • Haijun Chen
    • 2
  • Lixing Jiang
    • 3
    • 4
  • Daping Xiao
    • 5
  1. 1.Department of Clinical LaboratoryKunshan Hospital Affiliated to Nanjing University of Chinese MedicineKunshanChina
  2. 2.Department of Oncological SurgeryKunshan Hospital of Traditional Chinese MedicineKunshanChina
  3. 3.Department of Clinical LaboratoryWujin Hospital Affiliated to Jiangsu UniversityChangzhouChina
  4. 4.Department of General SurgeryWujin Hospital Affiliated to Jiangsu UniversityChangzhouChina
  5. 5.Department of Clinical LaboratoryThe 359th Hospital of PLAZhengjiangChina

Personalised recommendations